Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
McKesson
Boehringer Ingelheim
Medtronic

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

VIZIMPRO Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Vizimpro, and when can generic versions of Vizimpro launch?

Vizimpro is a drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty patent family members in forty-two countries.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this compound. Additional details are available on the dacomitinib profile page.

Summary for VIZIMPRO
Drug patent expirations by year for VIZIMPRO
Drug Prices for VIZIMPRO

See drug prices for VIZIMPRO

Generic Entry Opportunity Date for VIZIMPRO
Generic Entry Date for VIZIMPRO*:
Constraining patent/regulatory exclusivity:
FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIZIMPRO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 2
National Cancer Centre, SingaporePhase 2

See all VIZIMPRO clinical trials

Synonyms for VIZIMPRO
(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
(2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
(E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
1110813-31-4
1110813-31-4 pound not PF 299804 pound not PF-299804
2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-
2XJX250C20
AB0035896
ABP000126
AC-25915
AKOS025401818
AOB87383
AOB87735
BC261945
BCP02530
BDBM112499
C24H25ClFN5O2
CHEBI:132268
CHEBI:91466
CHEMBL2110732
CS-0500
D09883
D5450
Dacomitinib
Dacomitinib (INN)
Dacomitinib (PF299804, PF-00299804)
Dacomitinib (PF299804, PF299)
Dacomitinib (PF299804)
Dacomitinib [USAN:INN]
Dacomitinib anhydrous
Dacomitinib, PF299804
dacomitinibum
DB11963
DTXSID50149493
EX-A030
GTPL7422
HY-13272
J-500784
MFCD19443734
MLS006011275
NCGC00263185-09
PF 00299804
PF 00299804-03
PF-00299804
PF-00299804 dacomitinib
PF-00299804-03
PF-299
PF-299804
PF-299804 (Dacomitinib PF-00299804)
pf00299804
PF299
PF299804
PF299804|||PF299
Q-4059
QCR-174
RL00451
s2727
SB21754
SC-94589
SMR004703025
SW219155-1
UNII-2XJX250C20
US8623883, No. 2
Y0338
ZINC72266312

US Patents and Regulatory Information for VIZIMPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-001 Sep 27, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-001 Sep 27, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VIZIMPRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746999 301004 Netherlands   Start Trial PRODUCT NAME: DACOMITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT ERVAN, IN HET BIJZONDER DACOMITINIB MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1354 20190404
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
AstraZeneca
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.